Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 6/2010

01-06-2010 | Original Paper

Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma

Authors: Peng Xie, Jin-Bo Yue, Han-xi Zhao, Xin-Dong Sun, Li Kong, Zheng Fu, Jin-Ming Yu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2010

Login to get access

Abstract

Purpose

The purpose of this study was to evaluate the prognostic value of metabolic tumor volume (MTV) and metabolic index (MI) from fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with nasopharyngeal carcinoma (NPC).

Methods

From October 2002 to July 2004, 41 patients with NPC who underwent 18F-FDG PET-CT scan before and after radiotherapy were reviewed retrospectively. All patients received intensity-modulated radiotherapy using 6MV X-rays. We examined the association of MTV and the results of long-term follow-up of the patients.

Results

Patients having tumors with an MTV below 30 cm3 had significantly better 5-year overall survival (OS) (84.6:46.7%, P = 0.006) and disease-free survival (DFS) (73.1:40.0%, P = 0.014) than patients with an MTV of 30 cm3 or greater. And the patients with MI below 130 had significantly higher 5-year OS (88.0:43.8%, P = 0.002) and DFS (76.0:37.5%, P = 0.005) than other patients. In the Cox multivariate analysis, MI and metabolic response (MR) were predictive of DFS, and we did not find a significant relationship between standard uptake value (SUV) and OS or DFS.

Conclusions

The present study shows that tumor volume parameters, especially the combination of MTV and SUV in the “metabolic index”, are valuable for predicting long-term survival. High MI may be useful for identifying patients requiring more aggressive treatment.
Literature
go back to reference Allal AS, Slosman DO, Kebdani T et al (2004) Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-18F-fluoro-2-deoxy-d-glucose. Int J Radiat Oncol Biol Phys 59:1295–1300PubMed Allal AS, Slosman DO, Kebdani T et al (2004) Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-18F-fluoro-2-deoxy-d-glucose. Int J Radiat Oncol Biol Phys 59:1295–1300PubMed
go back to reference Chan SC, Chang JT, Wang HM et al (2009) Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol 45:52–58CrossRefPubMed Chan SC, Chang JT, Wang HM et al (2009) Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol 45:52–58CrossRefPubMed
go back to reference Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586CrossRefPubMed Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586CrossRefPubMed
go back to reference Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 80:11–20CrossRef Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 80:11–20CrossRef
go back to reference Eschmann SM, Friedel G, Paulsen F et al (2006) Is standardized (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 33:263–269CrossRefPubMed Eschmann SM, Friedel G, Paulsen F et al (2006) Is standardized (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 33:263–269CrossRefPubMed
go back to reference Greven KM, Williams DW 3rd, McGuirt WF Sr et al (2001) Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23:942–946CrossRefPubMed Greven KM, Williams DW 3rd, McGuirt WF Sr et al (2001) Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23:942–946CrossRefPubMed
go back to reference Grow A, Quon A, Graves EE et al (2005) Metabolic tumor volume as an independent prognostic factor in lymphoma. J Clin Oncol (ASCO Ann Meeting Proc Suppl) 23:6594 Grow A, Quon A, Graves EE et al (2005) Metabolic tumor volume as an independent prognostic factor in lymphoma. J Clin Oncol (ASCO Ann Meeting Proc Suppl) 23:6594
go back to reference Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–578CrossRefPubMed Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–578CrossRefPubMed
go back to reference Kao CH, Shiau YC, Shen YY et al (2002) Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission tomography. Cancer 94:1981–1986CrossRefPubMed Kao CH, Shiau YC, Shen YY et al (2002) Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission tomography. Cancer 94:1981–1986CrossRefPubMed
go back to reference Krishna SM, James S, Balaram P (2006) Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 115:85–90CrossRefPubMed Krishna SM, James S, Balaram P (2006) Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 115:85–90CrossRefPubMed
go back to reference La TH, Filion EJ, Turnbull BB et al (2009) Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 74:1335–1341PubMed La TH, Filion EJ, Turnbull BB et al (2009) Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 74:1335–1341PubMed
go back to reference Lee SW, Cho KJ, Park JH et al (2005) Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 62:1451–1457PubMed Lee SW, Cho KJ, Park JH et al (2005) Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 62:1451–1457PubMed
go back to reference Lee P, Weerasuriya DK, Lavori PW et al (2007) Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 69:328–333PubMed Lee P, Weerasuriya DK, Lavori PW et al (2007) Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 69:328–333PubMed
go back to reference Lee SW, Nam SY, Im KC et al (2008) Prediction of prognosis using standardized uptake value of 2-18F-fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 87:211–216CrossRefPubMed Lee SW, Nam SY, Im KC et al (2008) Prediction of prognosis using standardized uptake value of 2-18F-fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 87:211–216CrossRefPubMed
go back to reference Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626–1632CrossRefPubMed Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626–1632CrossRefPubMed
go back to reference Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805CrossRefPubMed Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805CrossRefPubMed
go back to reference Nahmias C, Hanna WT, Wahl LM et al (2007) Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med 48:744–751CrossRefPubMed Nahmias C, Hanna WT, Wahl LM et al (2007) Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med 48:744–751CrossRefPubMed
go back to reference Nakao K, Mochiki M, Nibu K et al (2006) Analysis of prognostic factors of nasopharyngeal carcinoma: impact of in situ hybridization for Epstein–Barr virus encoded small RNA 1. Otolaryngol Head Neck Surg 134:639–645CrossRefPubMed Nakao K, Mochiki M, Nibu K et al (2006) Analysis of prognostic factors of nasopharyngeal carcinoma: impact of in situ hybridization for Epstein–Barr virus encoded small RNA 1. Otolaryngol Head Neck Surg 134:639–645CrossRefPubMed
go back to reference Roedl JB, Halpern EF, Colen RR et al (2009) Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol 11:54–60CrossRefPubMed Roedl JB, Halpern EF, Colen RR et al (2009) Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol 11:54–60CrossRefPubMed
go back to reference Sasaki R, Komaki R, Macapinlac H et al (2005) [18F]Fluorodeoxy-glucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23:1136–1143CrossRefPubMed Sasaki R, Komaki R, Macapinlac H et al (2005) [18F]Fluorodeoxy-glucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23:1136–1143CrossRefPubMed
go back to reference Schwarz JK, Siegel BA, Dehdashti F et al (2008) Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 71:180–186PubMed Schwarz JK, Siegel BA, Dehdashti F et al (2008) Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 71:180–186PubMed
go back to reference Song SY, Kim JH, Ryu JS et al (2005) FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 63:1053–1059PubMed Song SY, Kim JH, Ryu JS et al (2005) FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 63:1053–1059PubMed
go back to reference Spiro SG, Buscombe J, Cook G et al (2008) Ensuring the right PET scan for the right patient. Lung Cancer 59:48–56CrossRefPubMed Spiro SG, Buscombe J, Cook G et al (2008) Ensuring the right PET scan for the right patient. Lung Cancer 59:48–56CrossRefPubMed
go back to reference Swisher SG, Maish M, Erasmus JJ et al (2004) Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78:1152–1160CrossRefPubMed Swisher SG, Maish M, Erasmus JJ et al (2004) Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78:1152–1160CrossRefPubMed
go back to reference Tsai MH, Shiau YC, Kao CH et al (2002) Detection of recurrent nasopharyngeal carcinomas with positron emission tomography using 18-fluoro-2-deoxyglucose in patients with indeterminate magnetic resonance imaging findings after radiotherapy. J Cancer Res Clin Oncol 128:279–282CrossRefPubMed Tsai MH, Shiau YC, Kao CH et al (2002) Detection of recurrent nasopharyngeal carcinomas with positron emission tomography using 18-fluoro-2-deoxyglucose in patients with indeterminate magnetic resonance imaging findings after radiotherapy. J Cancer Res Clin Oncol 128:279–282CrossRefPubMed
go back to reference van Rens MT, de la Riviere AB, Elbers HR et al (2000) Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117:374–379CrossRefPubMed van Rens MT, de la Riviere AB, Elbers HR et al (2000) Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117:374–379CrossRefPubMed
go back to reference van Tinteren H, Hoekstra OS, Smit EF et al (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359:1388–1393CrossRefPubMed van Tinteren H, Hoekstra OS, Smit EF et al (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359:1388–1393CrossRefPubMed
go back to reference Wang LF, Chai CY, Kuo WR et al (2006) Correlation between proliferating cell nuclear antigen and p53 protein expression and 5-year survival rate in nasopharyngeal carcinoma. Am J Otolaryngol 27:101–105CrossRefPubMed Wang LF, Chai CY, Kuo WR et al (2006) Correlation between proliferating cell nuclear antigen and p53 protein expression and 5-year survival rate in nasopharyngeal carcinoma. Am J Otolaryngol 27:101–105CrossRefPubMed
go back to reference Wieder HA, Beer AJ, Lordick F et al (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46:2029–2034PubMed Wieder HA, Beer AJ, Lordick F et al (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46:2029–2034PubMed
go back to reference Wong RJ, Lin DT, Schoder H et al (2002) Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20:4199–4208CrossRefPubMed Wong RJ, Lin DT, Schoder H et al (2002) Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20:4199–4208CrossRefPubMed
go back to reference Xu X, Yu J, Sun X et al (2008) The prognostic value of 18F-fluorodeoxyglucose uptake by using serial positron emission tomography and computed tomography in patients with stage III non-small cell lung cancer. Am J Clin Oncol 31:470–475CrossRefPubMed Xu X, Yu J, Sun X et al (2008) The prognostic value of 18F-fluorodeoxyglucose uptake by using serial positron emission tomography and computed tomography in patients with stage III non-small cell lung cancer. Am J Clin Oncol 31:470–475CrossRefPubMed
go back to reference Yeh SA, Tang Y, Lui CC et al (2005) Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 62:672–679PubMed Yeh SA, Tang Y, Lui CC et al (2005) Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 62:672–679PubMed
Metadata
Title
Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma
Authors
Peng Xie
Jin-Bo Yue
Han-xi Zhao
Xin-Dong Sun
Li Kong
Zheng Fu
Jin-Ming Yu
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 6/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-009-0729-7

Other articles of this Issue 6/2010

Journal of Cancer Research and Clinical Oncology 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.